High Throughput Screening for Inhibitors of Mycobacterium tuberculosis H 37 Rv

SUBRAMANIAM ANANTHAN1a, ELLEN R. FAALEOLEA2a, ROBERT C. GOLDMAN3a, JUDITH V. HOBRATH1b, CECIL D. KWONG1c, BARBARA E. LAUGHON3b, JOSEPH A. MADDRY1d, ALKA MEHTA1e, LYNN RASMUSSEN1f, ROBERT C. REYNOLDS1g, JOHN A. SECRIST III1h,*, NICE SHINDO1i, DUSTIN N. SHOWE2b, MELINDA I. SOSA1j, WILLIAM J. SULING1k, and E. LUCILE WHITE1l 1aSouthern Research Institute, 2000 Ninth Avenue South, Birmingham, AL 35205 USA, Fax: 205-581-2726, 205-581-2822, ananthan@southernresearch.org

[1]  Amita Jain,et al.  Extensively Drug-Resistant Mycobacterium tuberculosis, India , 2007, Emerging infectious diseases.

[2]  L. Bekker,et al.  Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[3]  L. A. Basso,et al.  Electron transfer kinetics and mechanistic study of the thionicotinamide coordinated to the pentacyanoferrate(III)/(II) complexes: a model system for the in vitro activation of thioamides anti-tuberculosis drugs. , 2005, Journal of inorganic biochemistry.

[4]  F. Hadizadeh,et al.  Synthesis of α-[5-(5-amino-1,3,4-thiadiazol-2-yl)-2-imidazolylthio]acetic acids , 2008 .

[5]  A. Neher,et al.  Extensively drug resistant tuberculosis in a high income country: A report of four unrelated cases , 2008, BMC infectious diseases.

[6]  P. Ortiz de Montellano,et al.  Oxidative activation of thiacetazone by the Mycobacterium tuberculosis flavin monooxygenase EtaA and human FMO1 and FMO3. , 2006, Chemical research in toxicology.

[7]  K. Kliiman,et al.  Clinical and operational value of the extensively drug-resistant tuberculosis definition , 2007, European Respiratory Journal.

[8]  R. Gibbs,et al.  Amide-substituted farnesylcysteine analogs as inhibitors of human isoprenylcysteine carboxyl methyltransferase. , 2006, Bioorganic & medicinal chemistry letters.

[9]  David Eisenberg,et al.  A Novel Inhibitor of Mycobacterium tuberculosis Pantothenate Synthetase , 2007, Journal of biomolecular screening.

[10]  L. Scheibel,et al.  Antimalarial activity of selected aromatic chelators. , 1980, Molecular pharmacology.

[11]  E. De Clercq,et al.  Structure−Activity Relationship Studies of a Series of Antiviral and Antibacterial Aglycon Derivatives of the Glycopeptide Antibiotics Vancomycin, Eremomycin, and Dechloroeremomycin , 2005 .

[12]  E. Chan,et al.  Treatment outcomes in extensively resistant tuberculosis. , 2008, The New England journal of medicine.

[13]  G. Schuster,et al.  8-Hydroxyquinolines with the Potential for Long-Term Anticaries Activity: Design, Synthesis, and In Vitro Evaluation , 1978, Journal of dental research.

[14]  C. Bertozzi,et al.  Drug Targeting Mycobacterium tuberculosis Cell Wall Synthesis: Development of a Microtiter Plate-Based Screen for UDP-Galactopyranose Mutase and Identification of an Inhibitor from a Uridine-Based Library , 2003, Antimicrobial Agents and Chemotherapy.

[15]  M. N. Nasr,et al.  Synthesis and In Vitro Antibacterial Evaluation of Novel Imidazo[2′, 1′:5, 1]‐1, 2, 4‐triazolo[4, 3‐c]‐quinazoline Derivatives of 5‐Thioxo‐1, 2, 4‐triazole, 4‐Oxothiazolidine, and their Open‐chain Counterparts , 2003, Archiv der Pharmazie.

[16]  A. Verkman,et al.  Small molecules with antimicrobial activity against E. coli and P. aeruginosa identified by high‐throughput screening , 2006, British journal of pharmacology.

[17]  P. Selzer,et al.  Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.

[18]  Sharon S. Choi,et al.  Comprehensive treatment of extensively drug-resistant tuberculosis. , 2008, The New England journal of medicine.

[19]  A. Kozikowski,et al.  Design, Synthesis, and Pharmacological Evaluation of Mefloquine‐Based Ligands as Novel Antituberculosis Agents , 2007, ChemMedChem.

[20]  P. Brennan,et al.  N-D-aldopentofuranosyl-N'-[p-(isoamyloxy)phenyl]-thiourea derivatives: potential anti-TB therapeutic agents. , 2008, Bioorganic & medicinal chemistry letters.

[21]  M. Laurenzi,et al.  Challenges associated with current and future TB treatment. , 2007, Infectious disorders drug targets.

[22]  S. Schenone,et al.  N-acylated and N,N'-diacylated imidazolidine-2-thione derivatives and N,N'-diacylated tetrahydropyrimidine-2(1H)-thione analogues: synthesis and antiproliferative activity. , 2009, European journal of medicinal chemistry.

[23]  D. Sriram,et al.  Synthesis and antimicrobial activities of some novel substituted 2-imidazolyl-N-(4-oxo-quinazolin-3(4H)-yl)-acetamides. , 2007, Chemical & pharmaceutical bulletin.

[24]  I. Orme,et al.  Rapid Microbiologic and Pharmacologic Evaluation of Experimental Compounds against Mycobacterium tuberculosis , 2006, Antimicrobial Agents and Chemotherapy.

[25]  P. Brennan,et al.  Isoxyl Activation Is Required for Bacteriostatic Activity against Mycobacterium tuberculosis , 2007, Antimicrobial Agents and Chemotherapy.

[26]  Rahul Jain,et al.  Synthesis, anti-tuberculosis activity, and 3D-QSAR study of 4-(adamantan-1-yl)-2-substituted quinolines. , 2007, Bioorganic & medicinal chemistry.

[27]  S. Franzblau,et al.  Low-Oxygen-Recovery Assay for High-Throughput Screening of Compounds against Nonreplicating Mycobacterium tuberculosis , 2007, Antimicrobial Agents and Chemotherapy.

[28]  Z. Tao,et al.  Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics. , 2007, Bioorganic & medicinal chemistry letters.

[29]  A. Katritzky,et al.  Solid phase synthesis and application of trisubstituted thioureas. , 2003, Journal of combinatorial chemistry.

[30]  M. Parry,et al.  Selective thromboxane synthetase inhibitors. 1. 1-[(Aryloxy)alkyl]-1H-imidazoles. , 1985, Journal of medicinal chemistry.

[31]  K. Weismann.  Chelating drugs and zinc. , 1986, Danish medical bulletin.

[32]  K. Kliiman,et al.  Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases , 2008, European Respiratory Journal.

[33]  S. Meshnick,et al.  Molecular Basis for Atovaquone Binding to the Cytochrome bc1 Complex* , 2003, Journal of Biological Chemistry.

[34]  B. Hammock,et al.  Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. , 2005, Journal of medicinal chemistry.

[35]  Martin Wu,et al.  Genomic Approach to Identifying the Putative Target of and Mechanisms of Resistance to Mefloquine in Mycobacteria , 2005, Antimicrobial Agents and Chemotherapy.

[36]  G. Besra,et al.  EmbR2, a structural homologue of EmbR, inhibits the Mycobacterium tuberculosis kinase/substrate pair PknH/EmbR. , 2008, The Biochemical journal.

[37]  M. Espinal,et al.  The global situation of MDR-TB. , 2003, Tuberculosis.

[38]  H. Rubin,et al.  Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Maurizio Fermeglia,et al.  Antimycobacterial activity of new 3-substituted 5-(pyridin-4-yl)-3H-1,3,4-oxadiazol-2-one and 2-thione derivatives. Preliminary molecular modeling investigations. , 2005, Bioorganic & medicinal chemistry.

[40]  A. Albert,et al.  Selective Toxicity , 1973, Springer US.

[41]  Richard E. Lee,et al.  Nitrofurans as novel anti-tuberculosis agents: identification, development and evaluation. , 2007, Current topics in medicinal chemistry.

[42]  C. S. Reddy,et al.  Synthesis and antimicrobial activity of N-(substituted)-N'-(2,3-dihydro-2-oxido-5-benzoyl-1H-1,3,2-benzodiazaphosphol-2-yl) ureas. , 2003 .

[43]  G. Evan,et al.  Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. , 2007, The Journal of clinical investigation.

[44]  K. Castro,et al.  Tuberculosis trends in the United States, 1992-2001. , 2003, Tuberculosis.

[45]  Ted Cohen,et al.  Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness , 2004, Nature Medicine.

[46]  R. Slayden,et al.  Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs. , 2000, Biochemical pharmacology.

[47]  J. Yim,et al.  Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  S. Merali,et al.  Ubiquinone Synthesis and its Regulation in Pneumocystis carinii , 2006, The Journal of eukaryotic microbiology.

[49]  Y. Av‐Gay,et al.  A protein kinase inhibitor as an antimycobacterial agent. , 2001, FEMS microbiology letters.

[50]  R. Jain,et al.  Substituted 4-methylquinolines as a new class of anti-tuberculosis agents. , 2003, Bioorganic & medicinal chemistry letters.

[51]  Y. Zhuang,et al.  Suppression of Ulcerative Colitis in Mice by Orally Available Inhibitors of Sphingosine Kinase , 2008, Digestive Diseases and Sciences.

[52]  Linghang Zhuang,et al.  Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. , 2003, Journal of medicinal chemistry.

[53]  R. Durmaz,et al.  Synthesis and antimicrobial activity of electron rich olefin derived cyclic ureas. , 1996, Arzneimittel-Forschung.

[54]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[55]  Kate S Carroll,et al.  Drug targets in mycobacterial sulfur metabolism. , 2007, Infectious disorders drug targets.

[56]  Jordi Bolós,et al.  Structure-activity relationships of p38 mitogen-activated protein kinase inhibitors. , 2005, Mini reviews in medicinal chemistry.

[57]  S. Boyce,et al.  The search for novel TRPV1-antagonists: from carboxamides to benzimidazoles and indazolones. , 2006, Bioorganic & medicinal chemistry letters.

[58]  A. Malde,et al.  Synthesis, anti-tuberculosis activity, and 3D-QSAR study of ring-substituted-2/4-quinolinecarbaldehyde derivatives. , 2006, Bioorganic & medicinal chemistry.

[59]  A. Kozikowski,et al.  Design, Synthesis, and SAR Studies of Mefloquine‐Based Ligands as Potential Antituberculosis Agents , 2006, ChemMedChem.

[60]  R. Chisin,et al.  Formation of fluorine-18 labeled diaryl ureas--labeled VEGFR-2/PDGFR dual inhibitors as molecular imaging agents for angiogenesis. , 2008, Bioorganic & medicinal chemistry.

[61]  S. Royce,et al.  Extensively drug-resistant tuberculosis in california, 1993-2006. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[62]  Erin E. Carlson,et al.  Chemical probes of UDP-galactopyranose mutase. , 2006, Chemistry & biology.

[63]  Chi‐Huey Wong,et al.  Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention. , 2007, Journal of medicinal chemistry.

[64]  J. Domagala,et al.  Structure-activity relationships of 3-aminoquinazolinediones, a new class of bacterial type-2 topoisomerase (DNA gyrase and topo IV) inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[65]  D. Russell,et al.  Ubiquitin Trafficking to the Lysosome: Keeping the House Tidy and Getting Rid of Unwanted Guests , 2007, Autophagy.

[66]  D. Sriram,et al.  Synthesis, Antitubercular and Anticancer Activities of Substituted Furyl‐quinazolin‐3(4H)‐ones , 2007, Archiv der Pharmazie.

[67]  Scott G. Franzblau,et al.  Drug Targeting Mycobacterium tuberculosis Cell Wall Synthesis: Genetics of dTDP-Rhamnose Synthetic Enzymes and Development of a Microtiter Plate-Based Screen for Inhibitors of Conversion of dTDP-Glucose to dTDP-Rhamnose , 2001, Antimicrobial Agents and Chemotherapy.

[68]  A. Gori,et al.  Extensively Drug-resistant Tuberculosis, Italy and Germany , 2007, Emerging infectious diseases.

[69]  J. Jackson,et al.  Anti-tumor virus activity of copper-binding drugs. , 1977, Advances in experimental medicine and biology.

[70]  R. Chakraborty,et al.  Antibacterial activity of some 3-(arylideneamino)-2-phenylquinazoline-4(3H)-ones: synthesis and preliminary QSAR studies. , 2007, Molecules.

[71]  S. Kaur,et al.  Ring-substituted quinolines as potential anti-tuberculosis agents. , 2004, Bioorganic & medicinal chemistry.

[72]  Vipan Kumar,et al.  Synthesis and biological activity of novel antibacterial quinazolines. , 2004, Bioorganic & medicinal chemistry letters.

[73]  C. Aldrich,et al.  Inhibition of siderophore biosynthesis in Mycobacterium tuberculosis with nucleoside bisubstrate analogues: structure-activity relationships of the nucleobase domain of 5'-O-[N-(salicyl)sulfamoyl]adenosine. , 2008, Journal of medicinal chemistry.

[74]  P. Ortiz de Montellano,et al.  Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides. , 2007, Bioorganic & medicinal chemistry.

[75]  G. Besra,et al.  EthA, a Common Activator of Thiocarbamide-Containing Drugs Acting on Different Mycobacterial Targets , 2007, Antimicrobial Agents and Chemotherapy.

[76]  W. Rohde,et al.  INACTIVATION AND INHIBITION OF ROUS SARCOMA VIRUS BY COPPER‐BINDING LIGANDS: THIOSEMICARBAZONES, 8‐HYDROXYQUINOLINES, AND ISONICOTINIC ACID HYDRAZIDE * , 1977, Annals of the New York Academy of Sciences.

[77]  R. Reynolds,et al.  Programs to facilitate tuberculosis drug discovery: the tuberculosis antimicrobial acquisition and coordinating facility. , 2007, Infectious disorders drug targets.

[78]  J. Sacchettini,et al.  M. tuberculosis Rv2252 encodes a diacylglycerol kinase involved in the biosynthesis of phosphatidylinositol mannosides (PIMs) , 2006, Molecular microbiology.

[79]  R. Reynolds,et al.  Antimycobacterial agents. 1. Thio analogues of purine. , 2004, Journal of medicinal chemistry.

[80]  H. Rubin,et al.  Type II NADH: menaquinone oxidoreductase of Mycobacterium tuberculosis. , 2007, Infectious disorders drug targets.

[81]  M. Spigelman,et al.  New tuberculosis therapeutics: a growing pipeline. , 2007, The Journal of infectious diseases.

[82]  Gurdyal S Besra,et al.  Unique Mechanism of Action of the Thiourea Drug Isoxyl on Mycobacterium tuberculosis* , 2003, Journal of Biological Chemistry.

[83]  J. Whitcher,et al.  Hydroxyquinolines Inhibit Ribonucleic Acid-Dependent Deoxyribonucleic Acid Polymerase and Inactivate Rous Sarcoma Virus and Herpes Simplex Virus , 1976, Antimicrobial Agents and Chemotherapy.

[84]  D. Saini,et al.  High-Throughput Microplate Phosphorylation Assays Based on DevR-DevS/Rv2027c 2-Component Signal Transduction Pathway to Screen for Novel Antitubercular Compounds , 2005, Journal of biomolecular screening.

[85]  K. Berlin,et al.  Synthesis and bioactivity of some new N-aryl/alkyl/cyclohexyl-N'-(2,3-dihydro-2-oxo-4H-benz[e][1,3,2]oxazaphosphorin-2-yl) ureas. , 2005, Pest management science.

[86]  R. Borchardt.  Catechol O-methyltransferase. 2. In vitro inhibition by substituted 8-hydroxyquinolines. , 1973, Journal of medicinal chemistry.

[87]  Vikramdeep Monga,et al.  Ring-substituted quinolines. Part 2: Synthesis and antimycobacterial activities of ring-substituted quinolinecarbohydrazide and ring-substituted quinolinecarboxamide analogues. , 2004, Bioorganic & medicinal chemistry.

[88]  C. Lingwood,et al.  3'Sulfogalactolipid binding specifically inhibits Hsp70 ATPase activity in vitro. , 2003, Biochemistry.

[89]  Rahul Jain,et al.  3D-QSAR study of ring-substituted quinoline class of anti-tuberculosis agents. , 2006, Bioorganic & medicinal chemistry.

[90]  D. Crick,et al.  Expression, essentiality, and a microtiter plate assay for mycobacterial GlmU, the bifunctional glucosamine-1-phosphate acetyltransferase and N-acetylglucosamine-1-phosphate uridyltransferase. , 2008, The international journal of biochemistry & cell biology.

[91]  Vikramdeep Monga,et al.  Synthesis and antimycobacterial activities of ring-substituted quinolinecarboxylic acid/ester analogues. Part 1. , 2004, Bioorganic & medicinal chemistry.

[92]  S. Blower,et al.  Predicting the future of XDR tuberculosis. , 2007, The Lancet. Infectious diseases.

[93]  L. Gundersen,et al.  Synthesis, biological activity, and SAR of antimycobacterial 2- and 8-substituted 6-(2-furyl)-9-(p-methoxybenzyl)purines. , 2007, Bioorganic & medicinal chemistry.

[94]  K. Hevener,et al.  Synthesis and evaluation of nitrofuranylamides as novel antituberculosis agents. , 2004, Journal of medicinal chemistry.

[95]  C. Ackerley,et al.  Inhibition of Multidrug Resistance by AdamantylGb3, a Globotriaosylceramide Analog* , 2008, Journal of Biological Chemistry.

[96]  T. Weisbrod,et al.  Characterization of the Mycobacterium tuberculosis iniBAC Promoter, a Promoter That Responds to Cell Wall Biosynthesis Inhibition , 2000, Journal of bacteriology.

[97]  A. Shafiee,et al.  Synthesis and antimycobacterial activity of some alkyl [5-(nitroaryl)-1,3,4-thiadiazol-2-ylthio]propionates. , 2006, Bioorganic & medicinal chemistry letters.

[98]  E. De Clercq,et al.  Anti-HIV activity of N-1-adamantyl-4-aminophthalimide. , 1997, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[99]  P. Shukla,et al.  Synthesis and Biological Evaluation of Novel (L)-α-Amino Acid Methyl Ester, Heteroalkyl, and Aryl Substituted 1,4-Naphthoquinone Derivatives as Antifungal and Antibacterial Agents. , 2006 .

[100]  R. Jain,et al.  Recent advances in new structural classes of anti-tuberculosis agents. , 2005, Current medicinal chemistry.

[101]  S. Yee,et al.  Synthesis and antimycobacterial activity of 7-O-substituted-4-methyl-2H-2-chromenone derivatives vs Mycobacterium tuberculosis , 2005, Journal of enzyme inhibition and medicinal chemistry.

[102]  K. Bush,et al.  A MurF Inhibitor That Disrupts Cell Wall Biosynthesis in Escherichia coli , 2007, Antimicrobial Agents and Chemotherapy.

[103]  W. W. Barrow,et al.  anti‐HIV Natural Product (+)‐Calanolide A Is Active Against Both Drug‐Susceptible and Drug‐Resistant Strains of Mycobacterium tuberculosis. , 2004 .

[104]  L. Tanoue.  Facing Extensively Drug-Resistant Tuberculosis — A Hope and a Challenge , 2009 .

[105]  K. V. Ramseshu,et al.  Synthesis, analgesic, anti-inflammatory and antibacterial activities of some novel 2-butyl-3-substituted quinazolin-4-(3H)-ones. , 2005, Biological & pharmaceutical bulletin.

[106]  P. Shukla,et al.  Synthesis and biological evaluation of novel 1,4-naphthoquinone derivatives as antibacterial and antiviral agents. , 2005, Bioorganic & medicinal chemistry letters.

[107]  Carol Winter,et al.  Structure-based design, synthesis, and SAR evaluation of a new series of 8-hydroxyquinolines as HIF-1alpha prolyl hydroxylase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[108]  D. Janssen,et al.  The Prodrug Activator EtaA from Mycobacterium tuberculosis Is a Baeyer-Villiger Monooxygenase* , 2004, Journal of Biological Chemistry.

[109]  S. Gracheck,et al.  In Vitro and In Vivo Activities of PD 0305970 and PD 0326448, New Bacterial Gyrase/Topoisomerase Inhibitors with Potent Antibacterial Activities versus Multidrug-Resistant Gram-Positive and Fastidious Organism Groups , 2007, Antimicrobial Agents and Chemotherapy.

[110]  V. K. Tandon,et al.  Synthesis and evaluation of novel 1,4-naphthoquinone derivatives as antiviral, antifungal and anticancer agents. , 2004, Bioorganic & medicinal chemistry letters.

[111]  B. Walker,et al.  Discovery and biological evaluation of adamantyl amide 11beta-HSD1 inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[112]  K. Kliiman,et al.  Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[113]  K. Duncan.  Progress in TB drug development and what is still needed. , 2003, Tuberculosis.

[114]  L. Tanoue.  Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa , 2008 .

[115]  J. Schwartz,et al.  Novel carbamates as potent histamine H3 receptor antagonists with high in vitro and oral in vivo activity. , 1996, Journal of medicinal chemistry.

[116]  N. Lall,et al.  Activity of 7-methyljuglone derivatives against Mycobacterium tuberculosis and as subversive substrates for mycothiol disulfide reductase. , 2007, Bioorganic & medicinal chemistry.

[117]  Y Av-Gay,et al.  The eukaryotic-like Ser/Thr protein kinases of Mycobacterium tuberculosis. , 2000, Trends in microbiology.

[118]  N. Lall,et al.  Activity of 7-methyljuglone in combination with antituberculous drugs against Mycobacterium tuberculosis. , 2006, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[119]  D. Minnikin,et al.  Symmetrical and unsymmetrical analogues of isoxyl; active agents against Mycobacterium tuberculosis. , 2006, Bioorganic & medicinal chemistry letters.

[120]  N. Takaishi,et al.  Biologically active polycycloalkanes. 1. Antiviral adamantane derivatives. , 1975, Journal of medicinal chemistry.

[121]  R. Ahmad,et al.  Synthesis and bioevaluation of glycosyl ureas as alpha-glucosidase inhibitors and their effect on mycobacterium. , 2003, Bioorganic & medicinal chemistry.

[122]  K. Glaser,et al.  Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[123]  D. Plant,et al.  High-Throughput Screening of RNA Polymerase Inhibitors Using a Fluorescent UTP Analog , 2006, Journal of biomolecular screening.

[124]  J. Domagala,et al.  Synthesis and structural-activity relationships of 3-hydroxyquinazoline-2,4-dione antibacterial agents. , 2004, Bioorganic & medicinal chemistry letters.